With a focus on improving quality while maintaining the cost of care, providers and payers are evaluating various payment models that could improve patient outcomes using evidence-based treatment at lower costs to the healthcare system.
Insurers and provider groups are trying a variety of approaches on oncology reimbursement that will remove the incentive for oncologists to use expensive but not necessarily effective chemotherapy drugs and instead place the focus back on quality of care.
These approaches range from care management fees paid on top of drug costs to bundled payments and case rates that completely revamp the way oncologists are reimbursed. Representatives of provider groups and insurers described three separate value-based payment programs for oncology at the Pay for Performance Summit in San Francisco sponsored by Global Health Care, LLC, on March 3.
New cancer drugs are often not cost-effective, said Jennifer Malin, MD, PhD, medical director for oncology solutions and innovation at Anthem Inc. For example, there were 13 new cancer treatments approved by the FDA in 2012, and only one of these extended survival by 6 months. Two more extended survival by four to six weeks, she said, but the average cost of treatment per month for all these therapies is $5900.
Link to the complete article on AISHealth:
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More